Trial Profile

Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MEN 1611 (Primary) ; Trastuzumab (Primary) ; Fulvestrant
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms B-PRECISE-01
Sponsors Menarini Ricerche

15 May 2024 Status changed from active, no longer recruiting to completed.
23 May 2023 Planned End Date changed from 31 Jul 2022 to 21 Dec 2023.
23 May 2023 Planned primary completion date changed from 31 Jul 2022 to 21 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com